Positions

Selected Publications

Academic Article

Year Title Altmetric
2016 A heterozygous RAB27A mutation associated with delayed cytolytic granule polarization and hemophagocytic lymphohistiocytosisJournal of Immunology.  196:2492-2503. 2016
2015 Hydroxyurea decreases hospitalizations in pediatric patients with Hb SC and Hb SB+ thalassemiaJournal of Blood Medicine.  6:285-290. 2015
2015 Health-related quality of life in infants with sickle cell diseaseJournal of Pediatric Hematology/Oncology.  37:590-594. 2015
2015 Encephaloduroarteriosynangiosis and encephalomyoarteriosynangiosis for treatment of moyamoya syndrome in pediatric patients with sickle cell diseaseJournal of Neurosurgery: Pediatrics.  16:64-73. 2015
2015 Exploring Adult Care Experiences and Barriers to Transition in Adult Patients with Sickle Cell Disease.International journal of hematology & therapy.  1. 2015
2015 Patient-centered approach to designing sickle cell transition educationJournal of Pediatric Hematology/Oncology.  37:43-47. 2015
2012 Barriers in transition from pediatrics to adult medicine in sickle cell anemia.Journal of Blood Medicine.  3:105-112. 2012
2012 Rates of malignancy associated with juvenile idiopathic arthritis and its treatment.Arthritis and Rheumatism.  64:1263-1271. 2012
2010 Single institution series of nodular fasciitis in childrenJournal of Pediatric Hematology/Oncology.  32:354-357. 2010

Investigator On

  • A Phase 3 Randomized Trial for Newly Diagnosed High Risk B-precursor Acute Lymphoblastic Leukemia (ALL) Testing Clofarabine (IND# 73789, NSC # 606869) in the Very High Risk Stratum  awarded by CHILDREN'S HOSPITAL (PHILADELPHIA)
  • AALL1331: Risk-Stratified Randomized Phase III Testing of Blinatumomab (IND#100135, NSC#765986) in First Relapse of Childhood B-Lymphoblastic Leukemia (B-ALL)  awarded by CHILDREN'S HOSPITAL (PHILADELPHIA)
  • AAML 1031 - A Phase III Randomized Trial for Patients with De Novo AML Using Bortezomib (NSC# 681239) and Sorafenib (BAY 43-9006, NSC# 724772) for Patients with High Allelic Ratio FLT2/ITD  awarded by CHILDREN'S ONCOLOGY GROUP
  • AAML 1031 - Bayer  awarded by CHILDREN'S HOSPITAL (PHILADELPHIA)
  • AHOD1331 A Randomized Phase III Study of Brentuximab Vedotin (IND#117117) for Newly Diagnosed High-Risk Classical Hodgkin Lymphoma (cHL) in Children and Adolescents  awarded by CHILDREN'S HOSPITAL (PHILADELPHIA)
  • BIQSFP-COG AALL1131 11XS189 Per Case Reimbursement  awarded by CHILDREN'S HOSPITAL (PHILADELPHIA)
  • COG PCR - Per Case Reimbursement NIH National Clinical Trials Network (NCTN) Grant (U10CA180886) Successor to NIH COG Chair Grant (U10CA098543)  awarded by CHILDREN'S HOSPITAL (PHILADELPHIA)
  • COG PCR - Per Case Reimbursement NIH National Clinical Trials Network (NCTN) Grant (U10CA180886) Successor to NIH COG Chair Grant (U10CA098543)  awarded by CHILDREN'S HOSPITAL (PHILADELPHIA)
  • COG PCR - Per Case Reimbursement NIH National Clinical Trials Network (NCTN) Grant (U10CA180886) Successor to NIH COG Chair Grant (U10CA098543)  awarded by CHILDREN'S HOSPITAL (PHILADELPHIA)
  • CTSU: Phase II Supplemental Payments (N02-CM-62212)  awarded by CHILDREN'S HOSPITAL (PHILADELPHIA)
  • Intergroup Trial for Children or Adolescents with B-Cell NHL or B-AL: Evaluation of Rituximab Efficacy and Safety in High Risk Patients  awarded by CHILDREN'S HOSPITAL (PHILADELPHIA)
  • Novel Methods to Detect Gene-Environment Interactions in Treatment-Related Brain Tumors Among Childhood Cancer Survivors  awarded by University of Wisconsin-Milwaukee
  • Per Case Reimbursement COG NCORP Research Base  awarded by CHILDREN'S HOSPITAL (PHILADELPHIA)
  • Per Case Reimbursement: COG NCORP Research Base  awarded by CHILDREN'S HOSPITAL (PHILADELPHIA)
  • Per Case Reimbursement: COG NCORP Research Base  awarded by CHILDREN'S HOSPITAL (PHILADELPHIA)
  • Private Grant  awarded by TERUMO BCT, INC.
  • Private Grant  awarded by MILLENNIUM PHARMACEUTICALS, INC.
  • Private Grant  awarded by SANCILIO & COMPANY, INC.
  • Private Grant  awarded by GLOBAL BLOOD THERAPEUTICS, INC.
  • Private Grant  awarded by NOVARTIS PHARMACEUTICALS CORPORATION
  • Project EveryChild APEC14B1  awarded by CHILDREN'S HOSPITAL (PHILADELPHIA)
  • Project Everychild APEC14B1  awarded by CHILDREN'S ONCOLOGY GROUP
  • Prospective Evaluation of the Duration of Therapy for Thrombosis in Children (Kids-DOTT Trial)  awarded by ALL CHILDREN'S RESEARCH INSTITUTE
  • Prospective Evaluation of the Duration of Therapy for Thrombosis in Children (Kids-DOTT Trial)  awarded by ALL CHILDREN'S RESEARCH INSTITUTE
  • St. Baldrick's Foundation Supplemental Reimbursement  awarded by CHILDREN'S HOSPITAL (PHILADELPHIA)
  • St. Baldricks Fdn Supplemental Reimbursement  awarded by CHILDREN'S HOSPITAL (PHILADELPHIA)
  • The COVID-19 Anticoagulation in Children-Thromboprophylaxis (COVAC-TP) Trial  awarded by ALL CHILDREN'S RESEARCH INSTITUTE
  • The Kids - DOTT Trial  awarded by ALL CHILDREN'S RESEARCH INSTITUTE
  • Education And Training

  • UAB Hospital, Internship
  • UAB Hospital, Residency
  • UAB Hospital, Postdoctoral Fellowship
  • Doctor of Medicine, University of Alabama at Birmingham 2006
  • Bachelor's Degree in Political Science and Government, University of Alabama at Birmingham 2001
  • Full Name

  • Christina Bemrich-Stolz